切换至 "中华医学电子期刊资源库"

中华心脏与心律电子杂志 ›› 2022, Vol. 10 ›› Issue (03) : 147 -150. doi: 10.3877/cma.j.issn.2095-6568.2022.03.004

所属专题: 总编推荐

心血管急危重症

心力衰竭室性心律失常与心脏性猝死的研究及治疗进展
林志彬1, 邓运生1, 杨京山1, 曾庆春1,()   
  1. 1. 510515 广州,南方医科大学南方医院心血管内科
  • 收稿日期:2022-06-16 出版日期:2022-09-25
  • 通信作者: 曾庆春
  • 基金资助:
    国家自然科学基金(82070403)

The research advance on ventricular arrhythmia and sudden cardiac death in heart failure patients

Zhibin Lin1, Yunsheng Deng1, Jingshan Yang1, Qingchun Zeng1,()   

  1. 1. Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
  • Received:2022-06-16 Published:2022-09-25
  • Corresponding author: Qingchun Zeng
引用本文:

林志彬, 邓运生, 杨京山, 曾庆春. 心力衰竭室性心律失常与心脏性猝死的研究及治疗进展[J]. 中华心脏与心律电子杂志, 2022, 10(03): 147-150.

Zhibin Lin, Yunsheng Deng, Jingshan Yang, Qingchun Zeng. The research advance on ventricular arrhythmia and sudden cardiac death in heart failure patients[J]. Chinese Journal of Heart and Heart Rhythm(Electronic Edition), 2022, 10(03): 147-150.

心力衰竭是各种心脏疾病的终末表现,心力衰竭患者合并室性心律失常是临床上一种常见现象,室性心律失常是心力衰竭患者心脏性猝死的主要原因。通过研究心力衰竭患者室性心律失常发生机制和猝死风险,对患者进行危险分层并实施安全有效的干预措施,对于降低心力衰竭患者的死亡率及改善预后有重要临床意义。

[1]
Tang PT, Shenasa M, Boyle NG. Ventricular arrhythmias and sudden cardiac death[J]. Card Electrophysiol Clin, 2017, 9(4):693-708.
[2]
Roger VL. Epidemiology of Heart Failure: A Contemporary Perspective. Circ Res[J]. 2021, 128(10):1421-1434.
[3]
陈伟伟, 高润霖, 刘力生,等. «中国心血管病报告2017»概要[J].中国循环杂志, 2018, 33(1):1-8.
[4]
Hao G, Wang X, Chen Z, et al. China Hypertension Survey Investigators. Prevalence of heart failure and left ventricular dysfunction in China: the China Hypertension Survey, 2012-2015[J]. Eur J Heart Fail, 2019, 21(11):1329-1337.
[5]
Szabó BM, van Veldhuisen DJ, Crijns HJ, et al. Value of ambulatory electrocardiographic monitoring to identify increased risk of sudden death in patients with left ventricular dysfunction and heart failure[J]. Eur Heart J, 1994, 15(7):928-933.
[6]
Cho JH, Leong D, Cuk N,et al. Delayed repolarization and ventricular tachycardia in patients with heart failure and preserved ejection fraction[J]. PLoS One, 2021, 16(7):e0254641.
[7]
Skogestad J, Aronsen JM. Hypokalemia-induced arrhythmias and heart failure: new insights and implications for therapy[J]. Front Physiol, 2018, 9:1500.
[8]
Wang Y, Hill JA. Electrophysiological remodeling in heart failure[J]. J Mol Cell Cardiol, 2010, 48(4):619-632.
[9]
Tamariz L, Goldberger JJ, Palacio A, et al. The additive role of echocardiography in the screening for sudden death[J]. Echocardiography, 2019 , 36(3):451-457.
[10]
Zaman S, Goldberger JJ, Kovoor P. Sudden death risk-stratification in 2018-2019: The old and the new[J]. Heart Lung Circ, 2019, 28(1):57-64.
[11]
Narayanan K, Reinier K, Teodorescu C, et al. Left ventricular diameter and risk stratification for sudden cardiac death[J]. J Am Heart Assoc, 2014, 3(5):e001193.
[12]
Centurión OA, Alderete JF, Torales JM,et al. Myocardial fibrosis as a pathway of prediction of ventricular arrhythmias and sudden cardiac death in patients with nonischemic dilated cardiomyopathy[J]. Crit Pathw Cardiol, 2019, 18(2):89-97.
[13]
Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. ESC Scientific Document Group. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death[J]. Eur Heart J, 2022:ehac262.
[14]
Kanitsoraphan C, Rattanawong P, Mekraksakit P, et al. Baseline fragmented QRS is associated with increased all-cause mortality in heart failure with reduced ejection fraction: A systematic review and meta-analysis[J]. Ann Noninvasive Electrocardiol, 2019, 24(2):e12597.
[15]
Zile MA, Trayanova NA. Rate-dependent force, intracellular calcium, and action potential voltage alternans are modulated by sarcomere length and heart failure induced-remodeling of thin filament regulation in human heart failure: a myocyte modeling study[J]. Prog Biophys Mol Biol, 2016, 120(1-3):270-280.
[16]
Vrtovec B, Knezevic I, Poglajen G, et al. Relation of B-type natriuretic peptide level in heart failure to sudden cardiac death in patients with and without QT interval prolongation[J]. Am J Cardiol, 2013, 111(6):886-890.
[17]
Sessa F, Anna V, Messina G, et al. Heart rate variability as predictive factor for sudden cardiac death[J]. Aging (Albany NY), 2018 , 10(2):166-177.
[18]
Kiuchi MG, Nolde JM, Villacorta H, et al. New approaches in the management of sudden cardiac death in patients with heart failure-targeting the sympathetic nervous system[J]. Int J Mol Sci, 2019, 20(10):2430.
[19]
唐继志, 李忠杰, 方永生,等. 心衰患者自主神经功能与临床相关因素的研究[J].中华心血管病杂志, 2004(3):52-53.
[20]
Zakrzewska-Koperska J, Franaszczyk M, Bilińska Z,et al. Rapid and effective response of the R222Q SCN5A to quinidine treatment in a patient with Purkinje- related ventricular arrhythmia and familial dilated cardiomyopathy: a case report[J].BMC Med Genet, 2018, 19( 1) : 94.
[21]
Osman J, Tan SC, Lee PY, et al. Sudden cardiac death (SCD) - risk stratification and prediction with molecular biomarkers[J]. J Biomed Sci, 2019, 26(1):39.
[22]
Zhang ZH, Barajas-Martínez H, Xia H, et al. Distinct features of probands with early repolarization and brugada syndromes carrying SCN5A pathogenic variants[J]. J Am Coll Cardiol, 2021, 78(16):1603-1617.
[23]
Vaksmann G, Klug D. Efficacy of ivabradine to control ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia[J]. Pacing Clin Electrophysiol, 2018 , 41(10):1378-1380.
[24]
Schupp T, Behnes M, Kim SH,et al. Comparable risk of recurrent ventricular tachyarrhythmias in implantable cardioverter-defibrillator recipients treated with single beta-blocker or combined amiodarone[J]. Basic Clin Pharmacol Toxicol, 2021, 128(3):493-502.
[25]
Mujović N, Dobrev D, Marinković M, et al. The role of amiodarone in contemporary management of complex cardiac arrhythmias[J]. Pharmacol Res, 2020, 151:104521.
[26]
Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the american college of Cardiology/American heart association task force on clinical practice guidelines and the heart failure society of america[J]. Circulation, 2017, 136(6):e137-e161.
[27]
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: a report of the american college of cardiology/american heart association joint committee on clinical practice guidelines[J]. Circulation, 2022, 145(18):e895-e1032.
[28]
Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes[J]. N Engl J Med, 2015, 373(22):2117-2128.
[29]
Fernandes GC, Fernandes A, Cardoso R, et al. Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials[J]. Heart Rhythm, 2021, 18(7):1098-1105.
[30]
Goldenberg I, Huang DT, Nielsen JC. The role of implantable cardioverter-defibrillators and sudden cardiac death prevention: indications, device selection, and outcome[J]. Eur Heart J, 2020 , 41(21):2003-2011.
[31]
中华医学会心电生理和起搏分会, 中国医师协会心律学专业委员会. 植入型心律转复除颤器临床应用中国专家共识(2021)[J].中华心律失常学杂志, 2021, 25(4):280-299.
[32]
Knops RE, Olde Nordkamp LRA, Delnoy PHM, et al. PRAETORIAN Investigators. Subcutane ous or transvenous defibrillator therapy[J]. N Engl J Med, 2020, 383(6):526-536.
[33]
McDonagh TA, Metra M, Adamo M,et al. ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2021, 42(36):3599-3726.
[34]
Yalin K, Liosis S, Palade E, et al. Cardiac sympathetic denervation in patients with nonischemic cardiomyopathy and refractory ventricular arrhythmias: a single-center experience[J]. Clin Res Cardiol, 2021 , 110(1):21-28.
[35]
Kiuchi MG, Nolde JM, Villacorta H, et al. New approaches in the management of sudden cardiac death in patients with heart failure-targeting the sympathetic nervous system[J]. Int J Mol Sci, 2019, 20(10):2430.
[1] 李颖, 潘绍卿, 丁明岩, 孙丹丹, 曲海波, 侯培培, 朱芳. 实时三维超声心动图对高度房室传导阻滞伴射血分数保留的心力衰竭患者左束支区域起搏后左心室功能及同步性的评价[J]. 中华医学超声杂志(电子版), 2023, 20(04): 430-436.
[2] 刘一凡, 高迪, 董佳, 朱凯媛, 潘新, 张风雷, 徐大春, 鄢春喜. 可溶性生长刺激表达基因2蛋白对急性心力衰竭住院患者的预后评估价值[J]. 中华危重症医学杂志(电子版), 2023, 16(01): 13-19.
[3] 庞慧, 纵振坤, 郭鹏, 魏鹏, 郝林. CHA2DS2-VASc评分在心力衰竭患者血栓栓塞风险预测中的应用[J]. 中华危重症医学杂志(电子版), 2022, 15(04): 285-290.
[4] 郑珊珊, 郑哲, 黄洁, 廖中凯, 宋云虎, 房晓楠, 刘盛. 主动脉内球囊反搏作为心脏移植桥接治疗对晚期心力衰竭合并肺动脉高压患者的疗效[J]. 中华移植杂志(电子版), 2022, 16(05): 277-284.
[5] 孙雪峰. 肾素-血管紧张素-醛固酮系统抑制剂治疗伴有心力衰竭的慢性肾脏病[J]. 中华肾病研究电子杂志, 2022, 11(06): 301-306.
[6] 王震, 杨晓月, 苏康康, 王朝阳, 李少杰, 陈淑霞, 谷剑. β受体阻滞剂对心力衰竭合并房颤患者预后影响的研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(04): 479-482.
[7] 王志明, 黄岳青, 马庆华, 陈卫海, 孙勤, 殷人麟, 吴雁鸣, 叶福龙, 尤华, 黄敏. “专科-全科”一体化联合管理在老年非瓣膜性房颤合并心衰患者中的应用:一项倾向性评分匹配研究[J]. 中华临床医师杂志(电子版), 2022, 16(12): 1188-1193.
[8] 李明雪, 李子墨, 田建立. 血压与心力衰竭的关系:研究现状与挑战[J]. 中华临床医师杂志(电子版), 2022, 16(08): 805-809.
[9] 唐红燕, 丹海俊, 高志红, 张作阳, 翟书梅, 吴少玉, 张玉. 心脏彩色多普勒超声在冠心病慢性心力衰竭患者临床诊断中的应用[J]. 中华临床医师杂志(电子版), 2022, 16(07): 676-679.
[10] 宗蔚蔚, 徐冬梅, 张新月, 耿洁. 医护一体化管理模式对沙库巴曲缬沙坦治疗老年心力衰竭患者用药依从性及并发症的影响[J]. 中华临床医师杂志(电子版), 2022, 16(06): 588-592.
[11] 周燕媚, 孙雯, 林琳, 陈娟娟, 杜培丽, 张慧丽, 陈兢思, 杜丽丽, 陈敦金. 子痫前期并发心力衰竭的诊治和评估[J]. 中华产科急救电子杂志, 2022, 11(04): 228-233.
[12] 杨旭希, 郑吉洋, 陈秀梅, 陈淑玲, 杨峻青, 苏芝琪, 左咏臻, 广东省医师协会心力衰竭专业医师分会, 广东省护士协会介入护士分会. 慢性心力衰竭患者容量管理护理专家共识[J]. 中华介入放射学电子杂志, 2023, 11(03): 201-207.
[13] 张诚霖, 李学美, 巫惠心, 李晓燕. 心力衰竭患者容量管理护理质量评价指标体系的构建[J]. 中华心脏与心律电子杂志, 2023, 11(03): 173-178.
[14] 孔倩文, 刘姗, 曾彩虹, 曾庆春. 有氧运动和抗阻运动对心力衰竭患者心率变异性影响的观察性研究[J]. 中华心脏与心律电子杂志, 2023, 11(03): 160-164.
[15] 黎俊聪, 黄莹, 杨婵娟, 屠燕. 钠-葡萄糖共转运体2抑制剂治疗心力衰竭的研究进展[J]. 中华心脏与心律电子杂志, 2023, 11(01): 45-49.
阅读次数
全文


摘要